
|Articles|December 6, 2017
Dr. Pant on the Third-Line Setting for Metastatic CRC
Author(s)Shubham Pant, MD, MBBS
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).
Advertisement
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).
According to Pant, there are not many options for patients with CRC in the third-line setting. Currently, regorafenib (Stivarga) and TAS-102 are the only options for this setting.
Next-generation sequencing is important to determine targets for treatment, explains Pant.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































